Movement Alert｜Hims & Hers Health Inc. Falls 7.3% in Regular Trading, Q2 EPS Loss Far Exceeds Expectations as Company Swings to Loss

Market Focus08-11

On August 11, Hims & Hers Health Inc. declined 7.3% in regular trading, trading at $29.52/share, with turnover of $48.9 million.

On the news front, the company reported Q2 earnings with a per-share loss of $0.37, far exceeding the market consensus estimate of a $0.03-$0.05 loss, and sharply deteriorating from earnings of $0.17 per share in the year-ago quarter. Despite revenue of $753 million representing 38% year-over-year growth and beating expectations, gross margin plunged from 76% to 64%. Management attributed the margin compression to international business expansion and branded GLP-1 weight loss drug sales, which generated restructuring costs. The CFO indicated gross margins will remain below historical levels for the foreseeable future. The company raised its full-year revenue guidance to $3.1-$3.3 billion from a prior $2.8-$3.0 billion range. Morgan Stanley raised its price target to $28 from $21 while maintaining an Equalweight rating. Nevertheless, the magnitude of the loss overwhelmed positive revenue trends, pressuring shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104254874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104254874","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hims & Hers Health Inc. Falls 7.3% in Regular Trading, Q2 EPS Loss Far Exceeds Expectations as Company Swings to Loss","media":"Market Focus","content":"<p><p>On August 11, Hims & Hers Health Inc. declined 7.3% in regular trading, trading at $29.52/share, with turnover of $48.9 million.</p><p>On the news front, the company reported Q2 earnings with a per-share loss of $0.37, far exceeding the market consensus estimate of a $0.03-$0.05 loss, and sharply deteriorating from earnings of $0.17 per share in the year-ago quarter. Despite revenue of $753 million representing 38% year-over-year growth and beating expectations, gross margin plunged from 76% to 64%. Management attributed the margin compression to international business expansion and branded GLP-1 weight loss drug sales, which generated restructuring costs. The CFO indicated gross margins will remain below historical levels for the foreseeable future. The company raised its full-year revenue guidance to $3.1-$3.3 billion from a prior $2.8-$3.0 billion range. Morgan Stanley raised its price target to $28 from $21 while maintaining an Equalweight rating. Nevertheless, the magnitude of the loss overwhelmed positive revenue trends, pressuring shares.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hims & Hers Health Inc. Falls 7.3% in Regular Trading, Q2 EPS Loss Far Exceeds Expectations as Company Swings to Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hims & Hers Health Inc. Falls 7.3% in Regular Trading, Q2 EPS Loss Far Exceeds Expectations as Company Swings to Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, Hims & Hers Health Inc. declined 7.3% in regular trading, trading at $29.52/share, with turnover of $48.9 million.</p><p>On the news front, the company reported Q2 earnings with a per-share loss of $0.37, far exceeding the market consensus estimate of a $0.03-$0.05 loss, and sharply deteriorating from earnings of $0.17 per share in the year-ago quarter. Despite revenue of $753 million representing 38% year-over-year growth and beating expectations, gross margin plunged from 76% to 64%. Management attributed the margin compression to international business expansion and branded GLP-1 weight loss drug sales, which generated restructuring costs. The CFO indicated gross margins will remain below historical levels for the foreseeable future. The company raised its full-year revenue guidance to $3.1-$3.3 billion from a prior $2.8-$3.0 billion range. Morgan Stanley raised its price target to $28 from $21 while maintaining an Equalweight rating. Nevertheless, the magnitude of the loss overwhelmed positive revenue trends, pressuring shares.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1104254874","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104254874","pubTimestamp":1786455062,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, Hims & Hers Health Inc. declined 7.3% in regular trading, trading at $29.52/share, with turnover of $48.9 million.On the news front, the company reported Q2 earnings with a per-share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"走势警报|Hims & Hers Health Inc. 常规交易中下跌 7.3%，第二季度每股收益亏损远超预期，公司转为亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"On August 11, Hims & Hers Health Inc. declined 7.3% in regular trading, trading at $29.52/share, with turnover of $48.9 million.On the news front, the company reported Q2 earnings with a per-share loss of $0.37, far exceeding the market consensus estimate of a $0.03-$0.05 loss, and sharply deteriorating from earnings of $0.17 per share in the year-ago quarter. Despite revenue of $753 million representing 38% year-over-year growth and beating expectations, gross margin plunged from 76% to 64%. Management attributed the margin compression to international business expansion and branded GLP-1 weight loss drug sales, which generated restructuring costs. The CFO indicated gross margins will remain below historical levels for the foreseeable future. The company raised its full-year revenue guidance to $3.1-$3.3 billion from a prior $2.8-$3.0 billion range. Morgan Stanley raised its price target to $28 from $21 while maintaining an Equalweight rating. Nevertheless, the magnitude of the loss overwhelmed positive revenue trends, pressuring shares.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104254874","isCrawlerRequest":true}